Collaboration aimed at advancing the development and commercialization of companion diagnostics and clinical decision-making tools utilizing flow cytometry technology. This partnership represents a significant step in the field of precision medicine and holds the potential to enhance the efficiency and accuracy of patient treatment matching. Through this collaborative effort, BD and Navigate BioPharma aim to offer comprehensive solutions for pharmaceutical and biotechnology companies engaged in the development of tests that can effectively pair patients with the most appropriate treatments. This includes companion diagnostics, which are vital for ensuring that patients receive the most suitable therapies, particularly in the context of oncology and other diseases where targeted treatments can significantly improve outcomes. One of the key objectives of this collaboration is to address a critical need in the clinical trial field: the provision of an integrated solution that covers all aspects of diagnostics and companion diagnostic development, from method creation to commercialization. This holistic approach is expected to streamline the process, making it more efficient and cost-effective for drug developers, ultimately benefiting patients by accelerating access to personalized therapies. Flow cytometry, a technology that allows for the analysis of cells and biomolecules at a cellular level, plays a pivotal role in this collaboration. By combining BD’s extensive portfolio of flow cytometry instruments, reagents, software, and in vitro diagnostic (IVD) development services with Navigate BioPharma’s expertise in designing and validating biomarker assays for clinical trials and regulatory submissions, the collaboration aims to harness the full potential of flow cytometry technology to expedite the delivery of personalized therapies.
The collaboration also has broader aspirations. It will explore the development of high- sensitivity minimal residual disease monitoring assays, a critical component in cancer treatment allowing for precise tracking of cancer cells post-treatment. Additionally, the partners aim to offer flexible and integrated solutions that assist their collaborators in achieving their clinical and regulatory goals by leveraging the capabilities of flow cytometry. Beyond these immediate objectives, the collaboration intends to expand the scope of therapeutic options and biomarkers that can be analyzed using flow cytometry. This expansion
may encompass complex target and drug combinations, the study of rare cell populations, and investigations into cell signaling and function. By pushing the boundaries of what is possible with flow cytometry, BD and Navigate BioPharma aspire to contribute to the advancement of precision medicine and improve patient outcomes.